Abstract
This study pioneers the MRP2-CTCs-EMT axis in breast cancer, clarifying MRP2's role in CTC biology and EMT, providing a theoretical basis for combined targeting strategies to improve metastatic breast cancer management.
Introduction
Metastasis remains the primary cause of death in breast cancer patients. To successfully colonize distant organs, cancer cells must detach from the primary tumor, enter the circulatory system as Circulating Tumor Cells (CTCs), and survive both the physical stresses of the bloodstream and systemic therapies. A critical component of this survival strategy is Multidrug Resistance (MDR), often facilitated by efflux pumps such as Multidrug Resistance-associated Protein 2 (MRP2).
While the role of MRP2 in primary tumors is well-documented, its expression patterns within the heterogeneous population of CTCs—particularly as they undergo the Epithelial-Mesenchymal Transition (EMT)—have remained poorly understood. This study investigates the "MRP2-CTCs-EMT" axis to determine how phenotypic plasticity influences drug resistance mechanisms in transit.
Methods
The study involved a cohort of 52 breast cancer patients at Shenzhen People’s Hospital. Researchers employed a dual-technology approach to isolate and characterize CTCs:
- Canpatrol™ CTC Detection: This platform utilizes size-based filtration (8 μm pores) to capture CTCs, ensuring that cells which have downregulated epithelial surface markers during EMT are still collected.
- Multiplex RNA In Situ Analysis (MRIA): Captured cells were analyzed for the expression of epithelial markers (EpCAM, CK8/18/19), mesenchymal markers (Vimentin, Twist), and the target marker MRP2 mRNA. Leukocytes were excluded using the CD45 marker.
Based on marker expression, CTCs were classified into three subtypes: Epithelial (E-type), Hybrid (H-type), and Mesenchymal (M-type).
Results
CTC Detection and Subtyping
CTCs were successfully detected in 94.2% of the patient cohort, demonstrating the high sensitivity of the Canpatrol platform. The analysis revealed a diverse population of cells across the EMT spectrum.
The EMT-MRP2 Correlation
A significant finding was the positive correlation between EMT progression and MRP2 expression. As cells transitioned from the E-type to the more aggressive H-type and M-type, MRP2 expression increased significantly. Specifically, 85.9% of (H+M)-type CTCs were MRP2-positive, compared to 76.3% of E-type CTCs ($P < 0.001$). The quantitative EMT grade was positively correlated with both the MRP2(+) CTC count and overall MRP2 expression levels ($R = 0.283, P = 0.042$).
Clinical Associations
The study found that CTC subtypes and MRP2 status were linked to tumor burden. Patients with primary tumors larger than 2 cm exhibited significantly higher counts of H-type CTCs ($P = 0.044$) and MRP2(+) CTCs ($P = 0.039$). This suggests that hybrid-state cells may be particularly indicative of advanced disease and therapeutic resistance.
Discussion
The identification of the "MRP2-CTCs-EMT" axis suggests that MRP2 is not merely a static resistance marker but a dynamic adaptive feature upregulated during EMT. This transition allows CTCs to better survive the selective pressures of the circulatory system and evade chemotherapy.
The high prevalence of MRP2 in hybrid and mesenchymal CTCs highlights a potential therapeutic vulnerability. Combining standard chemotherapy with MRP2 inhibitors (e.g., probenecid) or EMT-targeting agents (e.g., TGF-β antagonists) could potentially "disarm" these cells, preventing them from establishing metastatic niches.
Conclusion
This study clarifies the relationship between phenotypic plasticity and multidrug resistance in breast cancer CTCs. While limited by its single-institution nature and sample size, the findings provide a strong theoretical foundation for using MRP2(+) CTCs as a predictive biomarker and a target for future combination therapies aimed at curbing metastasis.
Summary updated